The Taxonomy of Covalent Inhibitors
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Covalent enzyme inhibitors are widely applied as biochemical tools and therapeutic agents. As a complement to categorization of these inhibitors by reactive group or modification site, we present a categorization by mechanism, which highlights common advantages and disadvantages inherent to each approach. Established categories for reversible and irreversible covalent inhibition are reviewed with representative examples given for each class, including covalent reversible inhibitors, slow substrates, residue-specific reagents, affinity labels (classical, quiescent, and photoaffinity), and mechanism-based inactivators. The relationships of these categories to proteomic profiling probes (activity-based and reactivity-based) as well as complementary approaches such as prodrug and soft drug design are also discussed. A wide variety of strategies are used to balance reactivity and selectivity in the design of covalent enzyme inhibitors. Use of a shared terminology is encouraged to clearly convey these mechanisms, to relate them to prior use of covalent inhibitors in enzymology, and to facilitate the development of more effective covalent inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · cited 2×
“Targeted Covalent Inhibitors, which target a poorly-conserved non-catalytic nucleophile),(12) but here we attempt to use only previously established categories as a framework to classify enzyme inhibitors that use covalent bond formation in their mechanisms (Figure 1).”
BackgroundActivity-Based Protein Profiling: From Enzyme Chemistry to Proteomic Chemistry
Cravatt, B. F., Wright, A. T., & Kozarich, J. W. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.124125 · Cited by 1,270 · cited 1×
“The revolutionary combination of irreversible covalent inhibitors with chemical tags used for detection and purification has enabled proteome-wide determination of selectivity, reactivity, and target identification, as well as other applications.(71) Rather than selectively targeting one enzyme, these probes covalentl…”
BackgroundSolca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865 · cited 1×
“An FDA-approved kinase inhibitor of epidermal growth factor receptor (EGFR), afatinib, is an example of a classical affinity label that uses an acrylamide as the reactive group, and is sufficiently selective for therapeutic use (Figure 5).(38, 44, 53) A non-reactive analog of afatinib, in which the double bond in the…”
BackgroundJackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588 · cited 1×
“of covalent enzyme inhibition in drug and inhibitor design.(1-18) Briefly, some of the potential advantages of covalent inhibitors include: sustained duration of action leading to less frequent dosing, increased ligand efficiency, the ability to overcome competing endogenous ligands, enhanced capability of targeting s…”
BackgroundTargeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534 · cited 2×
“KI = [(k−1 + k2)/k1] × [(k3 + k4)/(k2 + k3 + k4)] (8)”
BackgroundStrategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193 · cited 1×
“of covalent enzyme inhibition in drug and inhibitor design.(1-18) Briefly, some of the potential advantages of covalent inhibitors include: sustained duration of action leading to less frequent dosing, increased ligand efficiency, the ability to overcome competing endogenous ligands, enhanced capability of targeting s…”
BackgroundTargeting biomolecules with reversible covalent chemistry
Bandyopadhyay, A., & Gao, J. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.08.011 · Cited by 143 · cited 2×
“E+I KI E ⋅ I catalyzed"off pathway" kinact E − I (5)”
Background
Cited by
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Ton, A., Gentile, F., Hsing, M., Ban, F., & Cherkasov, A. (2020) · Molecular Informatics · doi:10.1002/minf.202000028 · Cited by 517
Guedes, I. A., Pereira, F. S. S., & Dardenne, L. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01089 · Cited by 331
Reactive-cysteine profiling for drug discovery
Maurais, A. J., & Weerapana, E. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.010 · Cited by 167
Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment
Greenberg, B. M. (2024) · Neurologic Clinics · doi:10.1016/j.ncl.2023.07.006 · Cited by 10
Metadata
- Authors
- Tuley, A., & Fast, W.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-04-24
- Volume
- 57
- Issue
- 24
- Pages
- 3326-3337
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2801332174
- Cited by
- 157
- References
- 12
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Taxonomy of Covalent Inhibitors. https://app.cochat.ai/papers/10.1021/acs.biochem.8b00315
- The paper
- Tuley, A., & Fast, W. (2018). The Taxonomy of Covalent Inhibitors. Biochemistry. https://doi.org/10.1021/acs.biochem.8b00315
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.